M
Megan M. Davis
Researcher at University of Pennsylvania
Publications - 30
Citations - 3589
Megan M. Davis is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Chimeric antigen receptor & Medicine. The author has an hindex of 11, co-authored 19 publications receiving 1773 citations. Previous affiliations of Megan M. Davis include Children's Hospital of Philadelphia.
Papers
More filters
Journal ArticleDOI
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A. Fraietta,Simon F. Lacey,Elena Orlando,Iulian Pruteanu-Malinici,Mercy Gohil,Stefan Lundh,Alina C. Boesteanu,Yan Wang,Roddy S. O’Connor,Wei-Ting Hwang,Edward Pequignot,David E Ambrose,Changfeng Zhang,Nicholas Wilcox,Felipe Bedoya,Corin L. Dorfmeier,Fang Chen,Lifeng Tian,Harit Parakandi,Minnal Gupta,Regina M. Young,F. Brad Johnson,Irina Kulikovskaya,Li Liu,Jun Xu,Sadik H. Kassim,Megan M. Davis,Bruce L. Levine,Noelle V. Frey,Don L. Siegel,Alexander C. Huang,E. John Wherry,Hans Bitter,Jennifer Brogdon,David L. Porter,Carl H. June,J. Joseph Melenhorst +36 more
TL;DR: A mechanistically relevant population of CD27+PD-1–CD8+ CAR T cells expressing high levels of the IL-6 receptor predicts therapeutic response and is responsible for tumor control, and new features of CAR T cell biology are uncovered.
Journal ArticleDOI
CRISPR-engineered T cells in patients with refractory cancer
Edward A. Stadtmauer,Joseph A. Fraietta,Megan M. Davis,Adam D. Cohen,Kristy L. Weber,Eric Lancaster,Patricia A. Mangan,Irina Kulikovskaya,Minnal Gupta,Fang Chen,Lifeng Tian,Vanessa E. Gonzalez,Jun Xu,In-Young Jung,J. Joseph Melenhorst,Gabriela Plesa,Joanne Shea,Tina Matlawski,Amanda Cervini,Avery L. Gaymon,Stephanie Desjardins,Anne Lamontagne,January Salas-Mckee,Andrew D. Fesnak,Don L. Siegel,Bruce L. Levine,Julie K. Jadlowsky,Regina M. Young,Anne Chew,Wei-Ting Hwang,Elizabeth O. Hexner,Beatriz M. Carreno,Christopher L. Nobles,Frederic D. Bushman,Kevin R. Parker,Yanyan Qi,Ansuman T. Satpathy,Howard Y. Chang,Yangbing Zhao,Simon F. Lacey,Carl H. June +40 more
TL;DR: This first-in-human, phase 1 clinical trial was designed to test the safety and feasibility of multiplex CRISPR-Cas9 gene editing of T cells from patients with advanced, refractory cancer and found the persistence of the T cells expressing the engineered TCR was much more durable than in three previous clinical trials during which T cells were infused.
Journal ArticleDOI
B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
Adam D. Cohen,Alfred L. Garfall,Edward A. Stadtmauer,J. Joseph Melenhorst,Simon F. Lacey,Eric Lancaster,Dan T. Vogl,Brendan M. Weiss,Karen Dengel,Annemarie Nelson,Gabriela Plesa,Fang Chen,Megan M. Davis,Wei-Ting Hwang,Regina M. Young,Jennifer Brogdon,Randi Isaacs,Iulian Pruteanu-Malinici,Don L. Siegel,Bruce L. Levine,Carl H. June,Michael C. Milone +21 more
TL;DR: CART-BCMA infusions with or without lymphodepleting chemotherapy are clinically active in heavily-pretreated MM patients, and were associated with CD4:CD8 T cell ratio and frequency of CD45RO-CD27+CD8+ T cells in the pre-manufacturing leukapheresis product.
Journal ArticleDOI
Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer.
Julia Tchou,Yangbing Zhao,Bruce L. Levine,Paul J. Zhang,Megan M. Davis,J. Joseph Melenhorst,Irina Kulikovskaya,Andrea L. Brennan,Xiaojun Liu,Simon F. Lacey,Avery D. Posey,Austin D. Williams,Alycia So,Jose R. Conejo-Garcia,Gabriela Plesa,Regina M. Young,Shannon E. McGettigan,Jean S. Campbell,Robert H. Pierce,Jennifer M. Matro,Angela DeMichele,Amy S. Clark,Laurence J.N. Cooper,Lynn M. Schuchter,Robert H. Vonderheide,Carl H. June +25 more
TL;DR: It is concluded that intratumoral injections of mRNA c-Met-CAR T cells are well tolerated and evoke an inflammatory response within tumors, as none of the patients had study drug–related adverse effects greater than grade 1.
Journal ArticleDOI
Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
J. Joseph Melenhorst,Gregory M. Chen,Meng Wang,David L. Porter,Changya Chen,McKensie Collins,Peng Gao,Shovik Bandyopadhyay,Hongxing Sun,Ziran Zhao,Stefan Lundh,Iulian Pruteanu-Malinici,Christopher L. Nobles,Sayantan Maji,Noelle V. Frey,Saar Gill,Lifeng Tian,Irina Kulikovskaya,Minnal Gupta,David E Ambrose,Megan M. Davis,Joseph A. Fraietta,Jennifer Brogdon,Regina M. Young,Anne Chew,Bruce L. Levine,Don L. Siegel,Cécile Alanio,E. John Wherry,Frederic D. Bushman,Simon F. Lacey,Kai Tan,Carl H. June +32 more
TL;DR: In this article , the authors studied long-lasting CD19-redirected chimeric antigen receptor (CAR) T cells in two patients with chronic lymphocytic leukaemia who achieved a complete remission in 2010.